Syngen Biotech Co., Ltd.(TW:8279)
NT$80.90-0.80 (-0.98%)
TW:8279
Syngen Biotech Co., Ltd. financials statements
NT$80.90
At close:-0.80 (-0.98%)
Syngen Biotech Co., Ltd. (8279) Income Statement
Syngen Biotech Co., Ltd. Income Statement
Last quarter (Q3 2026), Syngen Biotech Co., Ltd.'s total revenue was NT$558.15M, a decrease of 0.90% from the same quarter last year. In Q3, Syngen Biotech Co., Ltd.'s net income was NT$63.71M. See Syngen Biotech Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| NT$ 2.14B | NT$ 2.01B | NT$ 1.84B | NT$ 1.93B | NT$ 1.47B | |
| NT$ 723.59M | NT$ 723.94M | NT$ 643.92M | NT$ 688.15M | NT$ 528.34M | |
| NT$ 396.61M | NT$ 413.72M | NT$ 341.06M | NT$ 307.96M | NT$ 246.54M | |
| Depreciation and Amortization | NT$ 121.33M | NT$ 114.69M | NT$ 99.47M | NT$ 86.50M | NT$ 81.40M |
| NT$ 448.31M | NT$ 423.57M | NT$ 442.14M | NT$ 448.88M | NT$ 380.42M | |
| NT$ 326.98M | NT$ 303.30M | NT$ 294.28M | NT$ 419.31M | NT$ 299.03M | |
| NT$ 7.86M | NT$ -3.69M | NT$ 39.52M | NT$ -22.89M | NT$ -3.53M | |
| NT$ 334.84M | NT$ 299.61M | NT$ 333.80M | NT$ 396.42M | NT$ 295.49M | |
| NT$ 271.59M | NT$ 240.21M | NT$ 274.83M | NT$ 321.24M | NT$ 237.77M | |
| Per Share Metrics | |||||
| Basic EPS | NT$ 10.02 | NT$ 8.86 | NT$ 10.14 | NT$ 11.85 | NT$ 8.77 |
| Diluted EPS | NT$ 10.02 | NT$ 8.85 | NT$ 10.13 | NT$ 11.84 | NT$ 8.76 |
| Weighted Average Shares Outstanding | 27.11M | 27.10M | 27.10M | 27.10M | 27.10M |
| Weighted Average Shares Outstanding (Diluted) | 27.11M | 27.13M | 27.13M | 27.13M | 27.13M |
Currency in TWD
